Genes & biomarkers

BCR::ABL1 fusion

BCR::ABL1 · Philadelphia chromosome · Ph+

A fusion important for targeted treatment and molecular monitoring in CML and related settings.

Sources checked · Introductory guide

On this page

What does this result mean?

An exchange between chromosomes 9 and 22 can join BCR and ABL1. The resulting Philadelphia chromosome is characteristic of CML. This acquired change is generally not passed to children.[1]

How does it connect to treatment?

ABL tyrosine kinase inhibitors such as imatinib or dasatinib are used in CML and selected Ph-positive ALL. Disease, phase, prior drugs and response guide the drug and any combination.[2]

What should I check in my report?

Initial positivity and the change in BCR::ABL1 levels during treatment are different information. Ask about quantitative PCR monitoring and comparison standards; do not stop medication based on one result alone.

Questions for your care team

  • How does my BCR::ABL1 level compare with earlier results, and when is the next test?
  • Which treatments or trials fit my cancer type, stage and previous treatment?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. MedlinePlus Genetics · Chronic myeloid leukemia (opens in a new tab)
  2. NCI · Dasatinib (opens in a new tab)
  3. NCI · Chronic Myeloid Leukemia Treatment (PDQ) (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

BCR::ABL1 fusion | Cancer Encyclopedia | My Chemo Diary